

David Taeb

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2586503/david-taieb-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

3,042
citations

30
h-index

51
g-index

144
ext. papers

4,011
ext. citations

6.7
avg, IF

5.47
L-index

#	Paper	IF	Citations
126	EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1977-95	8.8	193
125	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2015 , 21, 3888-95	12.9	175
124	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017 , 38, 489-515	27.2	151
123	68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 186-91	8.9	120
122	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2112-2137	8.8	113
121	18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 711-7	8.9	111
120	PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1784-91	8.8	106
119	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1949-1956	8.9	89
118	Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1248-57	8.8	80
117	Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma. <i>Journal of the Endocrine Society</i> , 2021 , 5, A168-A169	0.4	78
116	Modern nuclear imaging for paragangliomas: beyond SPECT. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 264-74	8.9	74
115	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2015 , 22, T135-45	5.7	65
114	The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 737-44	8.9	62
113	Genetics, diagnosis, management and future directions of research of pheochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020 , 38, 1443-1456	1.9	62
112	Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. <i>Neoplasia</i> , 2015 , 17, 55-65	6.4	49
111	First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E908-13	5.6	49
110	Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , 2016 , 23, 899-908	5.7	49

109	18F-FDOPA PET/CT imaging of insulinoma revisited. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 409-18	8.8	46
108	Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2465-2472	5.6	44
107	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18)F-FDOPA PET: focus on missed lesions. <i>Clinical Endocrinology</i> , 2013 , 79, 170-7	3.4	43
106	Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 630-5	1.7	40
105	Parathyroid scintigraphy: when, how, and why? A concise systematic review. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 568-74	1.7	39
104	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , 2019 , 26, R627-R652	5.7	39
103	Targeting NAD/PARP DNA Repair Pathway as a Novel Therapeutic Approach to -Mutated Cluster I Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2018 , 24, 3423-3432	12.9	38
102	Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 787-797	8.8	38
101	Persistent and recurrent hyperparathyroidism. <i>Updates in Surgery</i> , 2017 , 69, 161-169	2.9	35
100	Preoperative imaging for focused parathyroidectomy: making a good strategy even better. <i>European Journal of Endocrinology</i> , 2015 , 172, 519-26	6.5	35
99	(18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1027-33	8.8	33
98	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021 , 146, 56-73	7.5	32
97	Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2017 , 86, 645-651	3.4	28
96	PET imaging in ectopic Cushing syndrome: a systematic review. <i>Endocrine</i> , 2015 , 50, 297-305	4	28
95	Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1144-55	8.8	26
94	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. <i>Endocrine-Related Cancer</i> , 2015 , 22, M1-8	5.7	26
93	Health-related quality of life in thyroid cancer patients following radioiodine ablation. <i>Health and Quality of Life Outcomes</i> , 2011 , 9, 33	3	25
92	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1236-1242	8.9	24

91	Clinical, Diagnostic, and Treatment Characteristics of -Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , 2019 , 9, 53	5.3	24
90	¹⁸ F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 325-332	4.6	24
89	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , 2017 , 78, 162-175	1.7	23
88	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. <i>Cell and Tissue Research</i> , 2018 , 372, 393-401	4.2	23
87	The Evolving Role of Succinate in Tumor Metabolism: An F-FDG-Based Study. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1749-1755	8.9	22
86	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. <i>Trends in Endocrinology and Metabolism</i> , 2017 , 28, 807-817	8.8	22
85	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , 2014 , 81, 317-28	3.4	21
84	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. <i>Gland Surgery</i> , 2020 , 9, 105-123 ^{2.2}	2.2	21
83	Quantitative F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 278-282 ^{8.8}	8.8	20
82	Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 978-986	18.1	19
81	Tomoscintigraphy improves the determination of the embryologic origin of parathyroid adenomas, especially in apparently inferior glands: imaging features and surgical implications. <i>Journal of Nuclear Medicine Technology</i> , 2007 , 35, 135-9	1.1	18
80	Personalized management of pheochromocytoma and paraganglioma. <i>Endocrine Reviews</i> , 2021 ,	27.2	18
79	¹⁸ F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1574-1582	5.6	17
78	Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with GravesHyperthyroidism undergoing radioiodine therapy: a randomized controlled study. <i>European Journal of Endocrinology</i> , 2016 , 174, 491-502	6.5	16
77	Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2337-9	5.6	16
76	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , 2017 , 28, 302-307	4.2	16
75	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 473-81	4.8	15
74	Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. <i>Seminars in Nuclear Medicine</i> , 2013 , 43, 462-73	5.4	15

73	F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 812-821	8.8	13
72	HIF-2alpha: AchillesUheel of pseudohypoxic subtype paraganglioma and other related conditions. <i>European Journal of Cancer</i> , 2017 , 86, 1-4	7.5	13
71	Therapeutic Targeting of -Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. <i>Clinical Cancer Research</i> , 2020 , 26, 3868-3880	12.9	12
70	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 435-444	15.2	12
69	Early F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 686-695	8.8	12
68	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. <i>Cancers</i> , 2019 , 11,	6.6	11
67	Carbidopa-assisted F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. <i>Annals of Nuclear Medicine</i> , 2016 , 30, 659-668	2.5	11
66	Head-to-head comparison between F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 979-987	8.8	10
65	Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , 2015 , 10, 477-86	2.2	10
64	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. <i>International Journal of Cancer</i> , 2020 , 146, 2326-2335	7.5	10
63	Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?. <i>Thyroid</i> , 2021 , 31, 151-155	6.2	10
62	Contemporary review of large adrenal tumors in a tertiary referral center. <i>Anticancer Research</i> , 2014 , 34, 2581-8	2.3	10
61	MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. <i>Endocrine</i> , 2020 , 69, 496-503	4	9
60	High-resolution magic angle spinning (1)H nuclear magnetic resonance spectroscopy metabolomics of hyperfunctioning parathyroid glands. <i>Surgery</i> , 2016 , 160, 384-94	3.6	9
59	In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. <i>Surgery</i> , 2016 , 159, 1231-3	3.6	9
58	Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. <i>Medical and Biological Engineering and Computing</i> , 2016 , 54, 103-11	3.1	9
57	Value of I/Tc-sestamibi parathyroid scintigraphy with subtraction SPECT/CT in primary hyperparathyroidism for directing minimally invasive parathyroidectomy. <i>American Journal of Surgery</i> , 2019 , 217, 108-113	2.7	9
56	Prospective evaluation of Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. <i>Clinical Endocrinology</i> , 2018 , 89, 155-163	3.4	9

55	Little cell neoplasms: a new differential diagnosis for 18F-FDOPA-avid thyroid nodules?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 865-6	5.6	8
54	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	8
53	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021 , 27, 2989-2995	12.9	8
52	(18)F-DOPA: the versatile radiopharmaceutical. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1187-9	8.8	8
51	Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 35, 728-735	5.2	8
50	Intraindividual comparison of F-FDOPA and Ga-DOTATOC PET/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2021 , 94, 66-73	3.4	8
49	First report of harlequin syndrome as the presenting feature of Carney Triad: a diagnostic and imaging challenge. <i>Journal of Clinical Oncology</i> , 2012 , 30, e168-71	2.2	7
48	Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , 2016 , 23, R371-9	5.7	6
47	Comprehensive review of evaluation and management of cardiac paragangliomas. <i>Heart</i> , 2020 , 106, 1203-1210	3.1	5
46	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , 2021 , 12, 625312	5.7	5
45	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. <i>Cancers</i> , 2018 , 10,	6.6	5
44	Radioactive iodine ablation in low-risk thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 686	18.1	4
43	Delivering PET imaging results to cancer patients: steps for handling ethical issues. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2240-2241	8.8	4
42	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020 , 67, 9-19	4	4
41	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 643-645	8.9	4
40	Germline SUCLG2 Variants in Patients with Pheochromocytoma and Paraganglioma. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
39	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 519-528	3.4	4
38	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1849-54	8.9	3

37	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154297	12.7	3
36	Characterization of adrenocortical tumors by F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. <i>Surgical Oncology</i> , 2018 , 27, 231-235	2.5	3
35	Topographic diagnosis: respective roles of morphological and functional imaging. <i>Annales D'Endocrinologie</i> , 2013 , 74, 185-90	1.7	3
34	Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 3S-12S	8.9	3
33	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. <i>Hormone and Metabolic Research</i> , 2019 , 51, 414-418	3.1	3
32	Risk stratification of adrenal masses by [F]FDG PET/CT: Changing tactics. <i>Clinical Endocrinology</i> , 2021 , 94, 133-140	3.4	3
31	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 26S-33S	8.9	3
30	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. <i>Langenbeck's Archives of Surgery</i> , 2017 , 402, 787-798	3.4	2
29	Paraganglioma of the organ of Zuckerkandl associated with a somatic mutation: A case report. <i>Oncology Letters</i> , 2017 , 13, 1083-1086	2.6	2
28	PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1614-1615	27.4	2
27	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A F-FDOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , 2019 , 91, 879-884	3.4	2
26	Limited role of carbidopa-assisted F-FDOPA PET/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 697-707	2.5	2
25	Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. <i>Head and Neck</i> , 2020 , 42, 3133-3140	4.2	2
24	An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. <i>British Journal of Radiology</i> , 2016 , 89, 20160061	3.4	2
23	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 2-3	18.1	2
22	Values of Ga-DOTATOC and Carbidopa-assisted F-DOPA PET/CT for insulinoma localization. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	2
21	Sporadic Primary Pheochromocytoma: A Prospective Intra-Individual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Ga-DOTATATE, FDG, F-FDOPA, and F-FDA). <i>American Journal of Roentgenology</i> , 2021 ,	5.4	2
20	Predicting risk factors of postoperative hypocalcemia after total thyroidectomy: is safe discharge without supplementation possible? A large cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021 , 406, 2425-2431	3.4	2

19	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A F-FDOPA PET/CT study. <i>Head and Neck</i> , 2019 , 41, 1565-1571	4.2	1
18	Imaging secondary hyperparathyroidism. <i>American Journal of Roentgenology</i> , 2014 , 203, W552	5.4	1
17	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1347-1348	8.9	1
16	Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system. <i>Journal of Psychosocial Oncology</i> , 2018 , 36, 624-634	2.8	1
15	A Bright Future for Nuclear Endocrinology. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1S-2S	8.9	1
14	Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1020-1028	5.6	0
13	Familial hypocalciuric hypercalcemia: the challenge of diagnosis. <i>Endocrine</i> , 2021 , 1	4	0
12	A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement. <i>EJNMMI Research</i> , 2018 , 8, 99	3.6	0
11	A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. <i>Endocrine</i> , 2021 , 1	4	0
10	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. <i>European Journal of Radiology</i> , 2021 , 143, 109911	4.7	0
9	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. <i>American Journal of Roentgenology</i> , 2021 , 217, 1008-1009	5.4	0
8	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.. <i>European Journal of Cancer</i> , 2022 , 169, 32-41	7.5	0
7	Thyroid cancer recurrence in the HiLo trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 252	18.1	
6	Recent advances in the imaging of pheochromocytomas and paragangliomas. <i>International Journal of Endocrine Oncology</i> , 2017 , 4, 137-144	0.3	
5	A Large Adrenal Tumor With Marked 18F-Fluorodeoxyglucose Uptake. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 84-85	27.4	
4	An Uncommon Sinonasal Metastasis. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020 , 146, 868-870	3.9	
3	Oncogenic osteomalacia related to an intramuscular mesenchymal tumor of the scalene muscles. <i>Kidney International</i> , 2021 , 100, 245	9.9	
2	PET in medullary thyroid carcinoma 2021 ,		

- 1 18F-FDOPA PET/CT for Treatment Response Assessment **2021**, 471-479